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 Implication for health policy/practice/research/medical education:
This article focuses on development of a simple method for genotyping of IL28B polymorphisms. This study is recommended to 
researchers in the field of viral hepatitis.
Background: In 2009, 3 genome-wide association studies implicated IL28B single-nu-
cleotide polymorphisms (SNPs) as the strongest genetic pretreatment predictor of sus-
tained virological response (SVR) in hepatitis C infection. Recently, the American Associa-
tion for the Study of Liver Diseases (AASLD) and the European Association for the Study of 
the Liver (EASL) included IL28B testing in their guidelines. 
Objectives: The main aim of this study was to develop and validate a simple, rapid, and 
inexpensive polymerase chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) method for genotyping of common IL28B polymorphisms (rs12979860 and 
rs8099917).
Patients and Methods: Two methods were developed to genotype common IL28B pol-
ymorphisms: 1) PCR-sequencing as a reference method and 2) PCR-RFLP as a rapid and 
inexpensive method. Both polymorphisms were genotyped in 104 Iranian hepatitis C pa-
tients by both methods simultaneously. To validate the PCR-RFLP method, the PCR-RFLP 
genotyping results should be 100% concordant with the PCR-sequencing results.
Results: Genotyping of rs12979860 and rs8099917 by PCR-RFLP was concordant with 
PCR-sequencing in 104 (100%) individuals. The analytical sensitivity and specificity of 
the PCR-RFLP method for genotyping of both SNPs are 100%. Among these 104 patients 
with chronic hepatitis C, the frequency of the rs12979860 CC, CT and TT genotypes were 
40.4%, 47.1% and 12.5% and the frequency of the rs8099917 TT, GT and GG genotypes were 
59.6%, 35.6% and 4.8%, respectively. Also, three IL28B haplotypes (rs12979860-rs8099917) 
were found among our patients including C-T, T-G and T-T with 63.9%, 22.6% and 13.5% 
frequency, respectively. C-G haplotype was absent in all of our patients.
Conclusions: We have developed a validated, fast, and simple PCR-RFLP method for geno-
typing of common IL28B SNPs that is more cost-effective than sequencing.
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1. Background
Chronic hepatitis C infection remains a global public 
health concern and has a prevalence of approximately 
2.2% globally (1). Chronic hepatitis C infection is a major 
cause of cirrhosis and hepatocellular carcinoma (2). The 
standard of care (SOC) for treatment of chronic hepatitis 
C infection is pegylated interferon α plus ribavirin, which 
leads to sustained virological response (SVR) in about 
40%-60% of patients with hepatitis C virus (HCV) geno-
type 1 (3). It appears that Iranian HCV-infected patients 
respond better to SOC treatment (4). The cost of SOC 
treatment is relatively high, and this type of treatment 
may cause many undesirable side effects (5). Various fac-
tors have been proposed as predictors of SVR, including 
HCV genotype, HCV RNA levels, the dose and duration of 
therapy, body mass index, age, insulin resistance, gender, 
stage of fibrosis, and co-infection with other hepatitis 
viruses or HIV (6). In 2009, 3 genome-wide association 
studies (GWASs) demonstrated an impact of single-nu-
cleotide polymorphisms (SNPs) in the spanning region 
between IL28B and IL28A on interferon-based hepatitis 
C clearance (7-9), implicating rs12979860 and rs8099917 
as the strongest genetic determinants of SVR. According 
to these studies, the rs12979860 C and rs8099917 T alleles 
are associated with a higher rate of SVR, whereas the 
rs12979860 T and rs8099917 G alleles are linked to a lower 
rate of SVR and a higher rate of treatment failure. Also, 
it has been shown that the rs12979860 CC and rs8099917 
TT genotypes are strongly associated with spontaneous 
resolution of HCV infection (10, 11). There are various as-
pects of the clinical utilization of IL28B testing, but it ap-
pears that it can help clinicians in decision-making with 
regard to treatment (12, 13). Recently, the American Asso-
ciation for the Study of Liver Diseases (AASLD) included 
IL28B testing in its guidelines (14), with a recommenda-
tion grade of Class 2a and Level B. Several methods, such 
as DNA sequencing, Taqman® allelic discrimination as-
say, pyrosequencing, polymerase chain reaction-restric-
tion fragment length polymorphism (PCR-RFLP), and al-
lele-specific PCR, can be applied for genotyping of SNPs, 
such as IL28B polymorphisms (15). These methods vary 
in features, such as cost-effectiveness, reliability, equip-
ment needs, and technical issues.
PCR-RFLP, also known as cleaved amplified polymorphic 
sequences (CAPS), is a simple, reliable, relatively fast, and 
inexpensive method with minimum equipment require-
ments. RFLP is based on the creation or deletion of rec-
ognition site of a restriction endonuclease by nucleotide 
variations in the polymorphic site; thus, digestion of the 
PCR product containing the polymorphism with an ap-
propriate restriction endonuclease results in disparate 
electrophoretic patterns by polymorphism genotype.
2. Objectives
The aim of this study was to develop and validate a 
simple, rapid, and inexpensive PCR-RFLP method for ge-
notyping of common IL28B polymorphisms (rs12979860 
and rs8099917). Also, based on the genotyping results, 
we report the genotype and related haplotype frequency 
of IL28B SNPs (rs12979860 and rs8099917) in Iranian pa-
tients with chronic hepatitis C.
3. Patients and Methods
3.1. Study Population 
We selected 104 consecutive and unrelated Iranian 
chronic hepatitis C patients (88 males, 16 females) who 
were treated at Tehran Hepatitis Center (Tehran, Iran) 
and referred to Armin Pathobiology Laboratory (Tehran, 
Iran). All patients were positive for anti-HCV antibody, as 
confirmed by recombinant immunoblot assay (RIBA).
3.2. IL28B Genotyping by PCR-Sequencing
Genomic DNA was extracted from 200 µl buffy coat us-
ing the QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. 
Primers for PCR-sequencing and PCR-RFLP of rs12979860 
and rs8099917 polymorphisms were designed using 
Primer-Blast (16), considering the homology in the region 
between IL28B and IL28A genes. The primers are listed in 
Table 1. PCR was performed using Accupower® PCR PreMix 
(Bioneer, South Korea) with a 20 µl reaction tube type. 
Briefly, 100-300 ng of genomic DNA was amplified with 10 
pmol of rs12-F and rs12-R primers for the genomic region 
containing rs12979860 and 10 pmol of rs80-F and rs80-
R primers for the genomic region containing rs8099917. 
The  PCR temperature profile comprised 94°C for 5 min; 
35 cycles of 94°C for 20 s, 66°C for 20 s, and 72°C for 20 s; 
and 72°C for 5 min. The resulting PCR products were bi-
directionally sequenced using BigDye® Terminator V3.1 
Cycle Sequencing Kits (Applied Biosystems, Foster City, 
CA, USA) in a 3130 Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s 
instructions. Sequencing results were analyzed using 
Chromas Lite Version 2.01 (Technelysium).
3.3. IL28B Genotyping by PCR-RFLP
The PCR primers that were used for PCR-RFLP genotyp-
ing of rs8099917 SNP were the same as those for PCR-
sequencing of this polymorphism, but for PCR-RFLP of 
rs12979860 SNP, the rs12-F primer was used as the for-
ward primer and bst-R was the reverse primer. The DNA 192 Hepat Mon. 2012
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amount and primer concentration for the PCR mixture 
and the temperature profile for the PCR amplification 
were the same as those for PCR-sequencing method. For 
RFLP analysis, the PCR product of rs12979860 was digest-
ed with 10 units of Bsh1236I (BstUI) restriction endonucle-
ase (Fermentas, Vilnius, Lithuania), and the PCR product 
of rs8099917 was digested with 10 units of BseMI (BsrDI) 
restriction endonuclease (Fermentas, Vilnius, Lithuania) 
for one hour. The digestion products were separated on 
a 3% agarose gel alongside the GeneRulerTM 100 bp DNA 
Ladder (Fermentas, Vilnius, Lithuania). In each PCR-RFLP 
genotyping run, as a control for the enzymatic activity of 
Bsh1236I and BseMI, respectively, rs12979860 CC DNA and 
rs8099917 GG DNA were included.
3.4. Validation Protocol
For validation of the PCR-RFLP method, the PCR-RFLP ge-
notyping results of rs12979860 and rs8099917 should be 
100% concordant with the DNA sequencing results. Also, 
the reproducibility of the PCR-RFLP method was assessed 
by repeating the genotyping of both SNPs for 50 patients 
in an independent experiment.
3.5. Hardy-Weinberg Equilibrium and Haplotype Esti-
mation
The genotype distribution of rs12979860 and rs8099917 
was tested for Hardy-Weinberg equilibrium. Also, haplo-
type estimation of IL28B was performed using Arlequin 
version 3.5 software (17) and the expectation-maximiza-
tion algorithm.
4. Results
4.1. IL28B Genomic Region and PCR Primer Design
rs12979860 and rs8099917 are located in the 24 Kb 
genomic region between IL28B and IL28A genes. This 
genomic region contains few homologous sequences. 
rs12979860 is located 3 kb upstream of IL28B in one of 
these homologous regions, and rs8099917 is located 8 kb 
upstream of IL28B, but we did not find any homology in 
its genomic region (Figure 1). PCR primers were designed 
considering the homology in the rs12979860 genomic 
region. As we show in Figure 2B, the complementary se-
quence of rs12-R primer presentes just in about 30% se-
quence of the rs12979860 homologous region (the ge-
nomic region which is shown as B in the Figure 1); thus, 
the rs12-F and rs12-R primer pair binds specifically to 
the rs12979860 genomic region. Based on the specific 
primers which were designed for PCR-sequencing of 
rs12979860, we applied PCR-sequencing as the reference 
method. We designed another reverse primer (bst-R) for 
PCR-RFLP genotyping of rs12979860. As we show in Figure 
2C, this primer binds to its specific site with a conven-
tional mismatch, which results in better separation of 
digested PCR products by electrophoresis. Among the 
primers that were designed for PCR-RFLP genotyping of 
rs12979860, we selected a primer pair with the maximum 
number of mismatches to the homologous genomic re-
gion. Due to the absence of homology in the rs8099917 
genomic region, the primer design for this SNP did not 
require any special consideration.
4.2. PCR-Sequencing Set-Up
Amplification of genomic DNA with rs12-F and rs12-R 
primers produced a 746 bp DNA fragment. In this frag-
ment, rs12979860 is located 197 bp from the 5’ end of the 
forward primer (rs12-F). Figure 3C shows the rs12979860 
CT sequencing chromatogram.
Amplification of genomic DNA with rs80-F and rs80-R 
primers yielded a 552 bp DNA fragment. In this fragment, 
rs8099917 is located 229 bp from the 5’ end of the for-
ward primer (rs80-F). Figure 3D shows the rs8099917 GT 
sequencing chromatogram.
4.3. PCR-RFLP Set-Up
We used the rs12-F and bst-R primer pair for PCR-RFLP 
genotyping of rs12979860, which amplified a 241 bp DNA 
fragment. Digestion of this product with Bsh1236I in CC 
individuals produced 2 fragments of 196 and 45 bp; 3 frag-
ments of 241, 196, and 45 bp in CT individuals; and a 241 
bp fragment in TT individuals (Figure 3A). For PCR-RFLP 
genotyping of rs8099917, we used the same PCR product 
as that used for PCR-sequencing of rs8099917. Digestion 
of this 552 bp PCR product with BseMI in TT individuals 
produced a 552 bp DNA fragment; 3 fragments of 552, 322, 
and 230 bp in GT individuals; and 2 fragments of 322 and 
230 bp in GG individuals (Figure 3B). 
4.4. Validation Results
Genotyping of rs12979860 and rs8099917 by PCR-RFLP 
was concordant with PCR-sequencing in all 104 (100%) 
Figure 1. The Genomic Region Spanning Between IL28B and IL28A Genes, and the Location of Common IL28B Polymorphisms
IL28B rs12979860 SNP resides in the region A, which is homologous to region B193 Hepat Mon. 2012
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Figure 2. Primers for PCR Amplification of rs12979860 and Their Probable Binding Sites on IL28B Flanking Region
A) rs12979860 PCR-sequencing primers and the binding site on their specific genomic region; B) rs12979860 PCR-sequencing primers and the undesirable and 
probable primer binding site on the rs12979860 homologous genomic region; C) rs12979860 PCR-RFLP primers and the binding site on their specific genomic 
region; D) rs12979860 PCR-RFLP primers and the undesirable and probable primer binding site on the rs12979860 homologous genomic region; The underlined 
nucleotides represent the primer mismatches. The primer nucleotides denoted by asterisk are not present in the probable primer binding site
Figure 3 . PCR-RFLP Electrophoresis Results and PCR-Sequencing Chromatograms
A) rs12979860 PCR-RFLP genotyping, lanes no. 1, 3 & 4 were genotyped CT, lane no. 2 was genotyped CC and lane no. 5 was genotyped TT; B) rs8099917 
PCR-RFLP Genotyping, lanes no. 1, 3 & 4 were genotyped GT, lane no. 2 was genotyped TT and lane no. 5 was genotyped GG; C) rs12979860 CT sequencing 
chromatogram; D) rs8099917 GT sequencing chromatogram. L, 100 bp DNA ladder194 Hepat Mon. 2012
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SNP Primer Name Sequence
rs12979860
rs12-F 5’ GCGGAAGGAGCAGTTGCGCT 3’
rs12-R 5’ GTGCCTTCACGCTCCGAGCA 3’
bst-R 5’ GGGGCTTTGCTGGGGGAGTG 3’
rs8099917
rs80-F 5’ CCCACTTCTGGAACAAATCGTCCC 3’
rs80-R 5’ TCTCCTCCCCAAGTCAGGCAACC 3’
Table 1. Primers for PCR-Sequencing and PCR-RFLP Genotyping of rs12979860 and rs8099917 SNPs
individuals. The analytical sensitivity and specific-
ity of the developed PCR-RFLP method for genotyping of 
rs12979860 and rs8099917 are 100%. PCR-RFLP genotyping 
of rs12979860 and rs8099917 was reproducible in all 50 
(100%) patients in the duplication test. The genotype and 
allele frequencies of both SNPs are presented in Table 2. 
Also, 6 compound rs12979860/rs8099917 genotypes were 
observed among our patients—CC/TT, CT/GT, CT/TT, TT/
GT, TT/GG, and TT/TT—at the following frequencies: 40.4%, 
30.8%, 16.3%, 4.8%, 4.8%, and 2.9%, respectively. 
4.5. Hardy-Weinberg Equilibrium and Haplotype Esti-
mation Results
Both rs12979860 and rs8099917 genotype distributions 
were in Hardy-Weinberg equilibrium (P = 0.82 and P = 
0.86, respectively). According to the haplotype estima-
tion, 3 rs12979860-rs8099917 haplotypes were noted in 
our patients—C-T, T-G, and T-T—at frequencies of 63.9%, 
22.6%, and 13.5%, respectively. The C-G haplotype was ab-
sent from our patients.
5. Discussion
The identification of IL28B SNPs as the strongest base-
line predictor of SVR by recent GWASs (7-9) has improved 
our knowledge on the challenging interindividual varia-
tions in interferon-based treatment outcomes in HCV in-
fected patients. The disparate distributions of IL28B gen-
otypes in Caucasians, Asians, and Africans explains the 
different rates of SVR in these populations. Today, IL28B 
genotyping is included in the AASLD and the European 
Association for the Study of the Liver (EASL) guidelines (6, 
14). As a result, physicians should consider IL28B testing 
in hepatitis C patients, and laboratories should include 
IL28B genotyping in their hepatitis C test panel. The PCR-
RFLP method that we designed can be used to genotype 
IL28B in less than 5 hours in nearly every laboratory, with 
minimum equipment requirements for molecular diag-
nosis. The PCR-RFLP method passed all of the criteria for 
validation and reached 100% analytical specificity and 
sensitivity. The PCR-RFLP method for IL28B genotyping is 
more cost-effective than DNA sequencing and does not 
need the expensive capital equipments that are required 
for DNA sequencing. In this study on Iranian patients 
with chronic hepatitis C, the rs12979860 C and rs8099917 
T allele frequencies were 63.9% and 77.4%, respectively, 
similar to the 63.4% rs12979860 C allele frequency by Ge 
et al. in 871 European-American patients with chronic 
hepatitis C infection (7) and the 76.5% rs8099917 T allele 
frequency by Rauch et al. in 1015 patients (white popu-
lation) with chronic hepatitis C infection (18). Also, we 
described haplotypes that were tagged by rs12979860 
and rs8099917 SNPs. The impact of these haplotypes on 
outcomes of interferon-based treatment will be reported 
by our study group soon. In conclusion, we have devel-
oped a validated, fast, and simple PCR-RFLP method for 
genotyping of IL28B rs12979860 and rs8099917 SNPs that 
is more cost-effective than sequencing.
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Frequency, %
rs12979860
Genotype
CC
CT
TT
40.4
47.1
12.5
Allele
C
T
63.9
36.1
rs8099917
Genotype
TT
GT
GG
59.6
35.6
4.8
Allele
T
G
77.4
22.6
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